Peripheral Endovascular Intervention clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
open to eligible people ages 18 years and up
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations.
at UCLA
Our lead scientists for Peripheral Endovascular Intervention research studies include Quang Bui, MD.
Last updated: